TY  - JOUR
A1  - Diehl-Schmid, Janine
A1  - Licata, Abigail
A1  - Goldhardt, Oliver
A1  - Förstl, Hans
A1  - Yakushew, Igor
A1  - Otto, Markus
A1  - Anderl-Straub, Sarah
A1  - Beer, Ambros
A1  - Ludolph, Albert Christian
A1  - Landwehrmeyer, Georg Bernhard
A1  - Levin, Johannes
A1  - Danek, Adrian
A1  - Fliessbach, Klaus
A1  - Spottke, Annika
A1  - Fassbender, Klaus
A1  - Lyros, Epameinondas
A1  - Prudlo, Johannes
A1  - Krause, Bernd Joachim
A1  - Volk, Alexander
A1  - Edbauer, Dieter
A1  - Schroeter, Matthias Leopold
A1  - Drzezga, Alexander
A1  - Kornhuber, Johannes
A1  - Lauer, Martin
A1  - Grimmer, Timo
T1  - FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations
JF  - Translational Psychiatry
N2  - C9ORF72 mutations are the most common cause of familial frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). MRI studies have investigated structural changes in C9ORF72-associated FTLD (C9FTLD) and provided first insights about a prominent involvement of the thalamus and the cerebellum. Our multicenter, 18F-fluorodeoxyglucose positron-emission tomography study of 22 mutation carriers with FTLD, 22 matched non-carriers with FTLD, and 23 cognitively healthy controls provided valuable insights into functional changes in C9FTLD: compared to non-carriers, mutation carriers showed a significant reduction of glucose metabolism in both thalami, underscoring the key role of the thalamus in C9FTLD. Thalamic metabolism did not correlate with disease severity, duration of disease, or the presence of psychotic symptoms. Against our expectations we could not demonstrate a cerebellar hypometabolism in carriers or non-carriers. Future imaging and neuropathological studies in large patient cohorts are required to further elucidate the central role of the thalamus in C9FTLD.
KW  - diagnostic markers
KW  - psychiatric disorders
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225308
VL  - 9
ER  - 
TY  - JOUR
A1  - Wester, Hans Jürgen
A1  - Keller, Ulrich
A1  - Schottelius, Margret
A1  - Beer, Ambros
A1  - Philipp-Abbrederis, Kathrin
A1  - Hoffmann, Frauke
A1  - Šimeček, Jakub
A1  - Gerngross, Carlos
A1  - Lassmann, Michael
A1  - Herrmann, Ken
A1  - Pellegata, Natalia
A1  - Rudelius, Martina
A1  - Kessler, Horst
A1  - Schwaiger, Markus
T1  - Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
JF  - Theranostics
N2  - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.
KW  - acute myeloid leukemia
KW  - prognostic value
KW  - therapeutic target
KW  - chemokine receptor
KW  - CXCR4
KW  - lymphoma
KW  - in vivo imaging
KW  - positron emission tomography
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144537
VL  - 5
IS  - 6
ER  -